

Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2022

<https://marketpublishers.com/r/J18C50B873DEN.html>

Date: January 2022

Pages: 150

Price: US\$ 2,500.00 (Single User License)

ID: J18C50B873DEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Janus Kinase (JAK) Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Janus Kinase (JAK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Janus Kinase (JAK) Inhibitors Understanding

Janus Kinase (JAK) Inhibitors: Overview

Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway. These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing. Cytokines play key roles in controlling cell growth and the immune response. Many cytokines function by binding to and activating type I and type II cytokine receptors. These receptors in turn rely on the

Janus kinase (JAK) family of enzymes for signal transduction. Hence drugs that inhibit the activity of these Janus kinases block cytokine signalling. More specifically, Janus kinases phosphorylate activated cytokine receptors. These phosphorylated receptors in turn recruit STAT transcription factors which modulate gene transcription

Janus kinase (JAK) inhibitors are a new addition in the armamentarium of drugs in the treatment of autoimmune dermatoses. They have proven to be valuable in treating a variety of inflammatory dermatoses with lesser side effects compared to their biological counterparts.

Janus kinase (JAK) inhibitors are small molecules approximately 400 Da that could be administered as oral medicines. In addition, they are easy to reach the inside of cells and directly inhibit intracellular signaling molecules.

JAK inhibitors belong to a family of medicine called DMARDs (disease-modifying antirheumatic drugs). Three JAK inhibitors, baricitinib (Olmiant), tofacitinib (Xeljanz), and upadacitinib (Rinvoq), are approved by the FDA to treat rheumatoid arthritis.

Janus Kinase (JAK) Inhibitors Emerging Drugs Chapters

This segment of the Janus Kinase (JAK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Janus Kinase (JAK) Inhibitors Emerging Drugs

Gusacitinib - Asana BioSciences

Gusacitinib (ASN002) is a potent inhibitor of the Janus kinase (JAK) family (JAK1, JAK2, JAK3 and TYK2) and spleen tyrosine kinase (SYK). Autoimmune, inflammatory and immunological-based diseases, including atopic dermatitis, have complex pathogenesis that involve interactions between multiple cytokines and immune cells. JAK kinases play a significant role in these inflammatory conditions. The JAK kinases family (JAK1, JAK2, JAK3 and TYK2) is involved in signaling pathways of the Th2,

Th22, Th1 and Th17 cytokines involved in AD pathogenesis. Hence, JAK kinases play a significant role in inflammatory conditions, particularly those driven by cytokines. SYK is a vital mediator of immunoreceptor signaling in macrophages, neutrophils, mast cells, and B cells. SYK mediated signaling leads to increased release of inflammatory cytokines, lipid mediators, and various proteases. Activated B cells and macrophages also act as antigen presenting cells and potent activators of T cells in inflammatory conditions. SYK also plays a critical role in IL-17R signaling in keratinocytes and in keratinocyte proliferation and terminal differentiation.

Further product details are provided in the report.....

Janus Kinase (JAK) Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Janus Kinase (JAK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Janus Kinase (JAK) Inhibitors

There are approx. 50+ key companies which are developing the Janus Kinase (JAK) Inhibitors. The companies which have their Janus Kinase (JAK) Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Asana BioSciences.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Janus Kinase (JAK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Janus Kinase (JAK) Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Janus Kinase (JAK) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Janus Kinase (JAK) Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Janus Kinase (JAK) Inhibitors R&D. The therapies under development are focused on novel approaches for Janus Kinase (JAK) Inhibitors.

June 2020: Gilead Sciences and Galapagos announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The data from the double-blind, placebo-controlled, Phase 2 EQUATOR study and the EQUATOR-2 open-label extension study demonstrate filgotinib's durable efficacy and consistent safety profile in people with active PsA, and showed rapid and sustained reductions in inflammatory biomarkers in patients with moderate to severe PsA. The new analyses were presented at the European League against Rheumatism, EULAR, European E-Congress of Rheumatology 2020.

Janus Kinase (JAK) Inhibitors Report Insights

Janus Kinase (JAK) Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Janus Kinase (JAK) Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Janus Kinase (JAK) Inhibitors drugs?

How many Janus Kinase (JAK) Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Janus Kinase (JAK) Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Janus Kinase (JAK) Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to

overcome the limitation of existing therapies?

What are the clinical studies going on for Janus Kinase (JAK) Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Japan Tobacco/LEO Pharma

AbbVie

Incyte Corporation

Asana BioSciences

Suzhou Zelgen Biopharmaceuticals

Key Products

Gusacitinib

Contents

Introduction

Executive Summary

Janus Kinase (JAK) Inhibitors: Overview

- Structure
- Mechanism of Action

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Janus Kinase (JAK) Inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Janus Kinase (JAK) Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends

Janus Kinase (JAK) Inhibitors Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

- Comparative Analysis

Gusacitinib - Asana BioSciences

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

Drug Name: Company Name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

- Comparative Analysis

Drug Name: Company Name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Janus Kinase (JAK) Inhibitors Key Companies

Janus Kinase (JAK) Inhibitors Key Products

Janus Kinase (JAK) Inhibitors- Unmet Needs

Janus Kinase (JAK) Inhibitors- Market Drivers and Barriers

Janus Kinase (JAK) Inhibitors- Future Perspectives and Conclusion

Janus Kinase (JAK) Inhibitors Analyst Views

Janus Kinase (JAK) Inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Janus Kinase (JAK) Inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Janus Kinase (JAK) Inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/J18C50B873DEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/J18C50B873DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970